Search Results

Shinobi Therapeutics today announced a partnership with Panasonic Holdings Corp and Kyoto University’s Center for iPS Cell Research and Application (CiRA).

UC San Diego and Point Loma Nazarene University will host the 22nd Kyoto Prize Symposium to celebrate the 37th annual laureates of the Kyoto Prize, Japan’s highest private award for global achievement.

Astellas is opening a second location of Universal Cells, its wholly owned subsidiary, at a research campus in Japan and transferring 12 roles from Universal’s Seattle location.

YolTech Therapeutics, a biotech company pioneering in in vivo gene editing therapies, today announced participation in TIDES Asia 2024, March 19th to 21st, 2024, at the Westin Miyako Kyoto in Kyoto, Japan.

Ono Pharmaceutical Co., Ltd. announced that it entered into a five-year, university-wide strategic research alliance agreement with Harvard University aiming at validating novel therapeutic targets.

Virion Therapeutics, LLC announced promising safety results from the first-ever human data from its novel, first-in-class, checkpoint modifier immunotherapy, VRON-0200, for HBV functional cure, presented by Professor Grace Wong, M.D., from the Chinese University of Hong Kong, as a late breaker oral presentation at the 33rd Annual Meeting of APASL in Kyoto, Japan.

The 21st annual Kyoto Prize Symposium this week celebrates the three latest laureates of the Kyoto Prize, Japan’s highest private award for global achievement, during live and online events co-hosted by University of California, San Diego and Point Loma Nazarene University.

OMRON Healthcare Co., Ltd. based in Muko, Kyoto Prefecture, Japan, announced its presence at Heart Rhythm 2024, the Annual Meeting of the Heart Rhythm Society in the U.S. At Heart Rhythm 2024, the Company will showcase its upper-arm blood pressure monitor with ECG technology, Complete, and a series of home-use blood pressure monitors.

MiNA Therapeutics today announced a research collaboration and licensing agreement option with Nippon Shinyaku Co., Ltd. (Nippon Shinyaku; Headquarters: Kyoto; President: Toru Nakai), an innovation-driven Japanese-based pharmaceutical company focused on disease areas of high unmet medical need.

NS Pharma, Inc. (NS Pharma) announced that its parent company, Nippon Shinyaku Co., Ltd. (Nippon Shinyaku) – headquartered in Kyoto, Japan, entered into a joint research agreement with MiNA Therapeutics – headquartered in London, United Kingdom, to develop nucleic acid drugs for the potential treatment of intractable and rare diseases of the central nervous system.